Year: 2024
Type: conference-paper
Study design: Case Report
Abstract: Pulmonary Hypertension (PH) affects the right heart, and is characterized by high mean pulmonary arterial pressure (mPAP).Treprostinil is a drug for PH that dilates downstream blood vessels, reducing pressure, peripheral vascular resistance (PVR), and right ventricle (RV) workload.Combining clinical data and model-derived metrics, this work aims to better understand the impact of Treprostinil in the interplay between RV, proximal, and peripheral arteries.Data from two PH patients undergoing treatment, a responder and a non-responder, were compared.Metrics of RV function, proximal pulmonary artery (PA), RV-PA coupling, and PVR, were analyzed.Compared to the responder, the non-responder had worsened RV function (15% increase vs 20% decrease in end-systolic volume), impaired coupling (0.36 vs 0.60), and increased mPAP (89 vs 46mmHg) despite decreased PVR (38 vs 13 WU), significant dilation of proximal PA (15-45% vs 1-6%) with minimal angulation changes, and increased arterial stiffness (pulse wave velocity: 8 vs 4.2 m/s ).Findings suggest that Treprostinil is more effective in earlier stages of PH and that the large PA dilation in the non-responder might be a compensatory mechanism for insufficient downstream vasodilation.The study highlights the potential of computational models to provide markers to assess treatment responses and disease progression in PH, however further research with larger patient groups is needed.
Source: Computing in cardiology
Authors: Malak Ismail Sabry, Pablo Lamata, Ahmed Hassan, Onaiho O. Ojo, Magdi H. Yacoub, Adelaide De Vecchi
Institutions: King's College London, Cairo University, Imperial College London
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Siemens Healthineers
OpenAlex ID: W4405435241